Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation
International Journal of Developmental Neuroscience · 2023
DOI: 10.1002/jdn.10283 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Developmental Neuroscience, 2023. Verfasst von Marion Deon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculdade de Farmácia, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil. Hauptthemen laut MEDLINE: Maple Syrup Urine Disease, Liver Transplantation. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Hospital de Clínicas de Porto Alegre.
Abstract (Originalsprache)
Maple syrup urine disease (MSUD) is caused by a deficiency in the activity of the branched‐chain α‐ketoacid dehydrogenase (BCKD) complex, promoting the accumulation of the branched‐chain amino acids (BCAA) leucine, isoleucine, and valine, as well as their respective α‐keto acids. MSUD is an autosomal recessive hereditary metabolic disorder characterized by ketoacidosis, ataxia, coma, and mental and psychomotor retardation. The mechanisms involved in the brain damage caused by MSUD are not fully understood. Early diagnosis and treatment, as well as proper control of metabolic decompensation crises, are crucial for patients' survival and for a better prognosis. The recommended treatment consists of a high‐calorie diet with restricted protein intake and specific formulas containing essential amino acids, except those accumulated in MSUD. This treatment will be maintained throughout life, being adjusted according to the patients' nutritional needs and BCAA concentration. Because dietary treatment may not be sufficient to prevent neurological damage in MSUD patients, other therapeutic strategies have been studied, including liver transplantation. With transplantation, it is possible to obtain an increase of about 10% of the normal BCKD in the body, an amount sufficient to maintain amino acid homeostasis and reduce metabolic decompensation crises. However, the experience related to this practice is very limited when considering the shortage of liver for transplantation and the risks related to the surgical procedure and immunosuppression. Thus, the purpose of this review is to survey the benefits, risks, and challenges of liver transplantation in the treatment of MSUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculdade de Farmácia, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.
- Serviço de Genética Médica, HCPA, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.
- Residência em Análises Clínicas do Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
- Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.
- Programa de Pós-Graduação em Ciências Farmacêuticas, Porto Alegre, Rio Grande do Sul, Brazil.
ORCID-Profile: Gilian Guerreiro
Förderung
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Hospital de Clínicas de Porto Alegre
Zitieren
APA
Deon, M., Guerreiro, G., Girardi, J., Ribas, G., & Vargas, C. R. (2023). Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. International Journal of Developmental Neuroscience. https://doi.org/10.1002/jdn.10283
Vancouver
Deon M, Guerreiro G, Girardi J, Ribas G, Vargas CR. Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation. International Journal of Developmental Neuroscience. 2023. doi:10.1002/jdn.10283
BibTeX
@article{Deon2023,
author = {Deon, Marion and Guerreiro, Gilian and Girardi, Julia and Ribas, Graziela and Vargas, Carmen Regla},
title = {Treatment of maple syrup urine disease: Benefits, risks, and challenges of liver transplantation},
journal = {International Journal of Developmental Neuroscience},
year = {2023},
doi = {10.1002/jdn.10283}
}
EUVIMED